Does Cosentyx Affect Vaccine Response?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses immune responses. This reduces vaccine effectiveness, especially for live vaccines, which are contraindicated during treatment.[1]
Recommended Timing for Vaccines Before Starting Cosentyx
Administer all vaccines per guidelines before initiating Cosentyx. Live vaccines should be given at least 4 weeks prior to the first dose to allow immune response development. Non-live (inactivated) vaccines can be given closer to start but ideally weeks ahead for optimal antibody production.[1][2]
Vaccines During Cosentyx Treatment
Avoid live vaccines (e.g., MMR, varicella, oral polio) entirely while on Cosentyx due to dissemination risk. For non-live vaccines like influenza, COVID-19, pneumococcal, or shingles (recombinant), responses are blunted:
- Antibody titers drop 20-50% compared to healthy controls.
- Seroprotection rates for flu vaccine: ~50-70% vs. 90%+ in untreated.[3][4]
Timing mid-treatment yields lower protection; annual boosters may still underperform.
Timing Vaccines After Stopping Cosentyx
Immune recovery takes time post-discontinuation:
- Live vaccines: Wait 4+ weeks after last dose.
- Non-live vaccines: Can give sooner, but effectiveness improves after 3-6 months when IL-17 inhibition wanes.[1][2]
No data shows full recovery before 3 months; monitor titers if high-risk.
Key Clinical Data on Vaccine Response
| Vaccine Type | Timing Relative to Cosentyx | Seroprotection Rate | Notes |
|--------------|-----------------------------|---------------------|-------|
| Influenza (inactivated) | During treatment | 52-68% | Lower geometric mean titers [3] |
| Pneumococcal (PCV13) | During treatment | 40-60% | Reduced vs. placebo [4] |
| COVID-19 (mRNA) | During treatment | ~70% (2 doses) | Boosters help but suboptimal [5] |
| Shingles (Shingrix) | Before start | >90% | Preferred timing [1] |
Real-world studies confirm timing before or after treatment maximizes response; mid-treatment vaccination protects less reliably.[3][5]
Patient Risks and Alternatives
Patients on Cosentyx face higher infection risk post-vaccination if response is poor. Discuss with rheumatologist: pause therapy for high-priority vaccines (e.g., 4-week hold pre-vaccine) or prioritize non-live options. No patent data alters this; generics not yet available (U.S. patent expires ~2032).[6]
[1]: Cosentyx Prescribing Information, Novartis, 2023. https://www.cosentyx.com
[2]: CDC Guidelines on Immunization in Immunocompromised Adults, 2023.
[3]: Rheumatology (Oxford), 2020; DOI:10.1093/rheumatology/keaa099
[4]: Ann Rheum Dis, 2019; DOI:10.1136/annrheumdis-2018-214314
[5]: Vaccine, 2022; DOI:10.1016/j.vaccine.2022.03.041
[6]: DrugPatentWatch.com, secukinumab patents. https://www.drugpatentwatch.com/p/tradename/COSENTYX